Pinnacle Associates Ltd. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 5.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 90,503 shares of the company’s stock after buying an additional 4,716 shares during the period. Pinnacle Associates Ltd.’s holdings in Novo Nordisk A/S were worth $4,358,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in Novo Nordisk A/S by 20.6% during the 1st quarter. Geode Capital Management LLC now owns 28,778 shares of the company’s stock valued at $985,000 after purchasing an additional 4,910 shares during the period. Bank of Montreal Can lifted its position in Novo Nordisk A/S by 24.2% during the 2nd quarter. Bank of Montreal Can now owns 80,934 shares of the company’s stock valued at $3,470,000 after purchasing an additional 15,756 shares during the period. Harbour Capital Advisors LLC lifted its position in Novo Nordisk A/S by 4,188.9% during the 2nd quarter. Harbour Capital Advisors LLC now owns 22,088 shares of the company’s stock valued at $515,000 after purchasing an additional 21,573 shares during the period. Janney Montgomery Scott LLC lifted its position in Novo Nordisk A/S by 53.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 43,164 shares of the company’s stock valued at $1,851,000 after purchasing an additional 14,999 shares during the period. Finally, Bessemer Group Inc. lifted its position in Novo Nordisk A/S by 0.7% during the 2nd quarter. Bessemer Group Inc. now owns 33,388 shares of the company’s stock valued at $1,431,000 after purchasing an additional 247 shares during the period. Institutional investors and hedge funds own 6.17% of the company’s stock.

Shares of Novo Nordisk A/S (NVO) traded up $0.22 during mid-day trading on Friday, hitting $51.99. The stock had a trading volume of 1,551,783 shares, compared to its average volume of 1,472,353. The company has a market cap of $132,013.50, a PE ratio of 22.61, a PEG ratio of 3.09 and a beta of 0.63. Novo Nordisk A/S has a one year low of $32.83 and a one year high of $52.32.

NVO has been the topic of a number of research reports. BidaskClub upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Bank of America upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, September 6th. Zacks Investment Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Wednesday, September 13th. BNP Paribas cut Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. Finally, Morgan Stanley raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $55.00.

In related news, insider Eric S. Sprott purchased 50,000 shares of the stock in a transaction dated Wednesday, November 8th. The stock was bought at an average cost of $8.34 per share, with a total value of $417,000.00. Corporate insiders own 0.07% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/12/02/pinnacle-associates-ltd-raises-position-in-novo-nordisk-as-nvo.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.